# Beijing Suncadia Pharmaceuticals Co., Ltd trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Beijing Suncadia Pharmaceuticals Co., Ltd as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Beijing Suncadia Pharmaceuticals Co., Ltd: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/beijing-suncadia-pharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889349 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Alzheimer's Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889349) |
| August 17, 2026 | NCT07769242 | A Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1/2 | Recruiting | Solid Tumors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07769242) |
| July 31, 2026 | NCT07739160 | The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Recruiting | Acute Ischemic Stroke | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739160) |
| February 11, 2026 | NCT07404553 | A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2/3 | Recruiting | Hypercholesterolemia | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07404553) |
| January 20, 2026 | NCT07349615 | A Study of SHR-1918 In Participants With Hypertriglyceridemia | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 3 | Active not recruiting | Hypertriglyceridemia | 367 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349615) |
| December 15, 2025 | NCT07280936 | A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Active not recruiting | Obesity, Overweight | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07280936) |
| November 17, 2025 | NCT07230730 | A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 3 | Recruiting | Hyperlipidemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230730) |
| November 17, 2025 | NCT07230145 | A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Heart Failure | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230145) |
| August 21, 2025 | NCT07133815 | Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Homozygous Familial Hypercholesterolemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133815) |
| July 24, 2025 | NCT07083362 | Safety, Tolerability and Pharmacokinetic Study of HRS-8829 | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Completed | Acute Ischemia Stroke | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083362) |
| April 1, 2025 | NCT06905314 | A Single Ascending Dose of HRS-4029 in Healthy Subjects | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Acute Ischemic Stroke | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905314) |
| February 13, 2025 | NCT06825416 | A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 3 | Completed | Prevention of Arterial and Venous Thrombosis | 1,165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06825416) |
| December 13, 2024 | NCT06732648 | The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2/3 | Recruiting | Severe Cerebral Edema Following Large Hemispheric Infarction | 725 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732648) |
| December 9, 2024 | NCT06723652 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in... | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 3 | Completed | Homozygous Familial Hypercholesterolemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723652) |
| November 21, 2024 | NCT06700083 | A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Completed | Heart Failure | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700083) |
| June 24, 2024 | NCT06471218 | Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Hyperlipidemia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06471218) |
| February 28, 2024 | NCT06280768 | Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Completed | Atrial Fibrillation | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06280768) |
| January 23, 2024 | NCT06220123 | A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing... | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06220123) |
| October 31, 2023 | NCT06109831 | Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Hyperlipidemic | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06109831) |
| August 24, 2023 | NCT06009393 | Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Homozygous Familial Hypercholesterolemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06009393) |
| March 2, 2023 | NCT05752461 | SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Prevention of Venous Thromboembolism After Knee Arthroplasty | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05752461) |
| January 19, 2023 | NCT05690711 | A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Completed | Brain Swelling, Large Hemispheric Infarction | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05690711) |
| June 27, 2022 | NCT05432544 | Safety and Tolerability of SHR-1918 in Healthy Subjects | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Unknown | Hyperlipemia | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05432544) |
| May 11, 2022 | NCT05369767 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Unknown | Prevention of Arterial and Venous Thrombosis | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05369767) |
| April 15, 2022 | NCT05330208 | Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in... | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Terminated | Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05330208) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Recruiting | 5 |
| Not yet recruiting | 4 |
| Unknown | 2 |
| Active not recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Homozygous Familial Hypercholesterolemia | 3 |
| Hyperlipidemias | 3 |
| Heart Failure | 2 |
| Ischemic Stroke | 2 |
| Venous Thrombosis | 2 |
| Brain Edema | 1 |
| Obesity | 1 |
| Overweight | 1 |
| Atrial Fibrillation | 1 |
| Hypercholesterolemia | 1 |
| Hypertriglyceridemia | 1 |
| Diabetes Mellitus | 1 |
| Alzheimer Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Distilleries in the United States](https://specstream.ai/data/businesses/distilleries/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Skylight installation companies in the United States](https://specstream.ai/data/businesses/skylight-installation-companies/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
